Novo-Nordisk A/S(us:NVO)
68.03
-2.03%
Updated on 2025-04-02
Open:69.98
Close:68.03
High:70.00
Low:67.64
Prev Close:69.44
Volume:6.21M
Turnover:426.61M
Turnover Ratio:0.14%
Shares:4.44B
MarketCap:301.99B
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 1874 | 331371872 | 7.44% | 196 | 737 | 653 |
| 2024-03-31 | 1751 | 321136197 | 7.19% | 305 | 709 | 533 |
| 2023-12-31 | 1514 | 307472120 | 6.90% | 268 | 567 | 490 |
| 2023-09-30 | 1332 | 300559608 | 6.72% | 183 | 482 | 457 |
| 2023-06-30 | 1239 | 285379736 | 12.73% | 132 | 428 | 468 |
| 2023-03-31 | 1158 | 142922124 | 6.36% | 165 | 313 | 470 |
| 2022-12-31 | 1068 | 143477739 | 6.29% | 194 | 287 | 400 |
| 2022-09-30 | 962 | 138052308 | 6.11% | 69 | 298 | 406 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-06-30 | Jennison Associates Llc | 21220641 | 0.48% | 136027 | 0.65% |
| 2024-06-30 | Fmr Llc | 19494642 | 0.44% | 1890320 | 10.74% |
| 2024-06-30 | Morgan Stanley | 14610900 | 0.33% | 2599047 | 21.64% |
| 2024-06-30 | Bank Of America Corp /De/ | 14189363 | 0.32% | 1135632 | 8.70% |
| 2024-06-30 | Fisher Asset Management, Llc | 13370627 | 0.30% | -354091 | -2.58% |
| 2024-06-30 | Fayez Sarofim & Co | 12552088 | 0.28% | 736251 | 6.23% |
| 2024-06-30 | Price T Rowe Associates Inc /Md/ | 9503764 | 0.21% | 914542 | 10.65% |
| 2024-06-30 | Renaissance Technologies Llc | 9165374 | 0.21% | -1620700 | -15.03% |
| 2024-06-30 | Loomis Sayles & Co L P | 8897437 | 0.20% | 44905 | 0.51% |
| 2024-06-30 | Folketrygdfondet | 8838723 | 0.20% | 82689 | 0.94% |
About
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsv?rd, Denmark.
Address:Novo Allé 1
Website:http://www.novonordisk.com
Market Movers